[Effects of atorvastatin in multiple sclerosis]

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• Statins (HMG-CoA reductase inhibitors) are primarily used for cholesterol reduction and cardiovascular disease treatment.
• Emerging evidence suggests statins possess potent immunomodulatory properties.
• Previous studies indicate statins can reduce transplant rejection and offer protection in models of brain autoimmunity.

Purpose of the Study:

• To evaluate the immunomodulatory effects of statins in vitro and in vivo.
• To assess the potential of statins as a therapeutic agent for multiple sclerosis (MS).

Main Methods:

• In vitro studies analyzed statin effects on T cells, including adhesion molecules, cytokine balance, matrix metalloproteinase-9, and chemokine receptors.
• In vivo studies utilized three distinct animal models of MS to assess the efficacy of oral atorvastatin.
• Investigated pleiotropic immunomodulatory effects on antigen-presenting cells and T cell compartments.

Main Results:

• In vitro, statins demonstrated significant immunomodulatory actions on T cells, B cells, and cytokine profiles relevant to MS.
• Oral atorvastatin effectively prevented or reversed paralysis in animal models of MS.
• Atorvastatin exhibited broad immunomodulatory effects impacting key immune cell populations.

Conclusions:

• Statins are effective in vitro immunomodulators and show therapeutic promise for MS.
• Atorvastatin's demonstrated efficacy in animal models warrants further investigation in human clinical trials.
• Statins represent a potential new treatment avenue for multiple sclerosis and other autoimmune conditions.